For research use only. Not for therapeutic Use.
Nerigliatin (PF-04937319) is a glucokinase activator (GKA) with EC50 value of 154.4 ?μM, one of the most promising strategies for the treatment of type 2 diabetes mellitus[1].
Nerigliatin is designed to maintain glucose-lowering efficacy while mitigating the risk of hypoglycaemia observed with many other GKAs[2].
| Catalog Number | I008669 |
| CAS Number | 1245603-92-2 |
| Synonyms | N,N-dimethyl-5-[[2-methyl-6-[(5-methylpyrazin-2-yl)carbamoyl]-1-benzofuran-4-yl]oxy]pyrimidine-2-carboxamide |
| Molecular Formula | C22H20N6O4 |
| Purity | ≥95% |
| InChI | InChI=1S/C22H20N6O4/c1-12-8-24-19(11-23-12)27-21(29)14-6-17-16(5-13(2)31-17)18(7-14)32-15-9-25-20(26-10-15)22(30)28(3)4/h5-11H,1-4H3,(H,24,27,29) |
| InChIKey | MASKQITXHVYVFL-UHFFFAOYSA-N |
| SMILES | CC1=CC2=C(O1)C=C(C=C2OC3=CN=C(N=C3)C(=O)N(C)C)C(=O)NC4=NC=C(N=C4)C |
| Reference | [1]. Dzyurkevich MS, et al. Pyridoxine dipharmacophore derivatives as potent glucokinase activators for the treatment of type 2 diabetes mellitus. Sci Rep. 2017 Nov 22;7(1):16072. [2]. Amin NB, et al. Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes. Diabetes Obes Metab. 2015 Aug;17(8):751-9. |
